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Dietary geranylgeraniol can limit 
the activity of pitavastatin as a 
potential treatment for drug-
resistant ovarian cancer
Elizabeth de Wolf1, Marwan Ibrahim Abdullah1, Stefanie M. Jones1, Karen Menezes2, Darren 
M. Moss1, Falko P. Drijfhout  3, Sarah R. Hart4, Clare Hoskins1, Euan A. Stronach2 & Alan 
Richardson  1
Pre-clinical and retrospective studies of patients using statins to reduce plasma cholesterol have 
suggested that statins may be useful to treat cancer. However, prospective clinical trials have yet to 
demonstrate significant efficacy. We have previously shown that this is in part because a hydrophobic 
statin with a long half-life is necessary. Pitavastatin, the only statin with this profile, has not undergone 
clinical evaluation in oncology. The target of pitavastatin, hydroxymethylglutarate coenzyme-A 
reductase (HMGCR), was found to be over-expressed in all ovarian cancer cell lines examined and 
upregulated by mutated TP53, a gene commonly altered in ovarian cancer. Pitavastatin-induced 
apoptosis was blocked by geranylgeraniol and mevalonate, products of the HMGCR pathway, 
confirming that pitavastatin causes cell death through inhibition of HMGCR. Solvent extracts of human 
and mouse food were also able to block pitavastatin-induced apoptosis, suggesting diet might influence 
the outcome of clinical trials. When nude mice were maintained on a diet lacking geranylgeraniol, oral 
pitavastatin caused regression of Ovcar-4 tumour xenografts. However, when the animal diet was 
supplemented with geranylgeraniol, pitavastatin failed to prevent tumour growth. This suggests that 
a diet containing geranylgeraniol can limit the anti-tumour activity of pitavastatin and diet should be 
controlled in clinical trials of statins.
Ovarian cancer remains an inadequately treated disease. Most ovarian cancer patients initially respond to chemo-
therapy but unfortunately the majority of patients relapse with a recurrence of the disease which ultimately 
becomes resistant to chemotherapy. Although molecularly-targeted therapies are beginning to make an impact, 
for example, PARP inhibitors1, currently only 40% of patients survive beyond 5 years2. New therapies are needed 
and one solution to this is to redeploy drugs which are currently used to treat other diseases.
Statins reduce plasma cholesterol by inhibiting hydroxymethylglutarate Coenzyme-A reductase (HMGCR) to 
prevent the synthesis of mevalonate, a precursor to cholesterol, and the isoprenoids farnesol and geranylgeraniol3. 
These isoprenoids are used to covalently modify several small GTPases and anchor them to the cell membrane. 
Membrane localization is necessary for the function of many small GTPases and because several small GTPases 
are oncogenes, there is a mechanistic rationale for interfering with their prenylation in cancer. HMGCR is itself 
considered a metabolic oncogene. It promotes tumour growth and it co-operates with Ras to transform cells 
in colony forming assays4. Recent data suggest that expression of HMGCR can be increased in cancer cells by 
wild-type5 or gain-of-function mutants of TP536. Mutation of TP53 can often lead to increased p53 protein 
because of the loss of the MDM-2 dependant negative feedback loop that normally controls p53 protein levels. 
Considering that mutation of TP53 is an almost invariant feature of ovarian cancer7, HMGCR expression can be 
expected to be deregulated in a significant proportion of ovarian cancers. This hypothesis is supported by immu-
nohistochemical studies which have identified HMGCR expression in 65% of ovarian cancers8 as well as in other 
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cancer types9–11. In addition, inhibition of HMGCR by statins alters the expression of several genes contributing 
to carcinogenesis12. Taken together, these data suggest that inhibition of HMGCR by statins may be beneficial in 
the treatment of cancer. In support of this, epidemiological studies have found a link between statin use to control 
hypercholesterolemia and reduced mortality from various cancers13, including ovarian cancer14.
Despite these encouraging observations, prospective clinical trials repurposing statins to treat cancer have so 
far mostly been unimpressive (reviewed in ref. 13). The lack of success of statins in prospective clinical trials in 
various cancers is likely to have multiple causes. Many of these trials have used the dose of a statin which is typ-
ically used to treat hypercholesterolemia15–19. Such doses result in a plasma concentration of drug that falls well 
below the concentration we have shown to be necessary to cause cell death in vitro20. However, clinical trials using 
doses close to the maximum tolerated dose have also not succeeded21–25. Some clinical trials have also used the 
once daily dosing interval commonly used to treat hypercholesterolaemia15–17, 19, 26–28. In contrast, we have shown 
that continual inhibition of HMGCR is necessary to kill cells in vitro because 12 hour cycles of simvastatin expo-
sure interspersed with 12 hours “drug holiday” completely abrogates the cytotoxic activity of simvastatin in vitro20. 
This suggests that short half-life statins (e.g. simvastatin, t½ = 2–3 hours)29 given once daily to patients are unlikely 
to maintain adequate inhibition of HMGCR to be effective, particularly if high doses are not used. Hydrophobic 
statins may also be preferred because they are more potent inducers of cell death than the hydrophilic statins20. 
Pitavastatin is unique because it is the only statin which combines a suitably long metabolic half-life29 (11 hours) 
to allow continual inhibition of HMGCR by twice daily dosing, with a lipophilic structure which renders it a 
potent inhibitor of HMGCR. Clinical trials of pitavastatin in cancer have yet to be reported, yet the arguments 
presented above suggest it is the statin most likely to efficacious in the treatment of cancer.
To justify clinical trials of pitavastatin in ovarian cancer, we have evaluated its activity against a panel of 
ovarian cancer cell lines. We show that pitavastatin induces apoptosis in ovarian cancer cells. However, this can 
be suppressed by exposure of the cells to geranylgeraniol as well as by extracts from mouse chow and human 
foodstuffs, raising the possibility that dietary isoprenoids may impede the effectiveness of statins in animal studies 
and in clinical studies in oncology. Ovcar-4 ovarian cancer xenografts in mice fed a diet lacking geranylgeraniol 
regressed when treated with pitavastatin. However, when mice received a diet supplemented with geranylgeran-
iol, the tumour continued to grow. This suggests that patients’ diet must be controlled for statins to be maximally 
effective in the treatment of cancer. More generally, clinical trials of drugs which affect metabolic processes may 
need to take into account patients’ diet.
Results
We first confirmed that HMGCR is highly expressed in ovarian cancer cell lines. HMGCR expression was higher 
in all 12 cell lines examined, than in normal ovarian epithelial cells (Fig. 1a,b). This included Ovcar-4, COV-318, 
COV-362, FuOv1 and Ovsaho cells which have recently been recognized as the most authentic cell line models of 
high-grade serous ovarian cancer (HGSOC)30. To determine if dysfunction of TP53 might contribute to altered 
HMGCR expression in ovarian cancer cells, we ectopically expressed wild-type and R248W, R175H, and R273H 
gain-of-function p53 variants in SkOv-3 ovarian cancer cells which lack endogenous p53 protein31. P53 was not 
detected in the SkOv-3 cells transfected with the vector (Fig. 1c). Transfection with all three plasmids encoding 
TP53 and its variants led to increased levels of HMGCR compared to cells transfected with the vector (Fig. 1c). 
To determine if pre-existing mutations in TP53 also led to increased expression of HMGCR, we inhibited the 
expression of TP53 in Ovcar-3 cells which contain a mutation in TP53 encoding R248Q32. Four different siRNA 
directed to TP53 mRNA significantly decreased both levels of p53 and HMGCR protein and, consistent with 
TP53 regulating HMGCR expression, HMGCR mRNA was also reduced (Fig. 1d).
Pitavastatin inhibited the growth of a panel of ovarian cancer cells, including those considered most likely to 
represent HGSOC, grown as a monolayers (IC50 = 0.4–5 μM; Fig. 2a) or as spheroids (IC50 = 0.6–4 μM; Fig. 2b). 
This activity was reversed by the addition of the isoprenoid geranylgeraniol (Fig. 2c). Pitavastatin was able to 
inhibit the growth of cultures of cells which were relatively resistant to carboplatin, raising the possibility that 
pitavastatin might be useful in the treatment of drug-resistant disease (Fig. S1). Strikingly, when we compared 
cell lines derived from patients before (PEA1, PEO1) or after (PEA2, PEO4) the onset of clinical drug resistance33, 
pitavastatin was at least as potent in the chemotherapy-resistant cells as the chemotherapy-sensitive ones, suggest-
ing pitavastatin may be useful to treat chemotherapy-resistant disease (Fig. 2a). Pitavastatin induced apoptosis, 
evidenced by the increased activity of executioner caspases-3,7 as well as caspase-8 and caspase-9 in two separate 
cell lines, and induced PARP cleavage (Fig. 3a–c). The increase in PARP cleavage was also prevented by inclusion 
of mevalonate or geranylgeraniol but not by farnesol, suggesting that pitavastatin, like simvastatin20, even when 
used at these relatively high concentrations causes cell death by inhibiting the HMGCR pathway. Furthermore, 
pitavastatin increased the secretion in two cell lines of caspase-cleaved cytokeratin 18 (ccCK18, Fig. 3d), a poten-
tial biomarker of tumour cell apoptosis in cancer patients34.
These studies prompted us to evaluate the activity of pitavastatin in a xenograft model. In a preliminary study 
(Fig. S2), tumours in animals treated with pitavastatin calcium twice daily were 85% of the volume of tumours 
in animals treated with vehicle, even though the tumours recovered from the animals at the end of the experi-
ment contained 8–22 µM pitavastatin. We considered the possibility that dietary sources of geranylgeraniol might 
have bypassed the inhibition of HMGCR by pitavastatin. Mouse chow contains significant quantities of fat and 
several human food stuffs (e.g. rice, oils) have also been shown to contain geranylgeraniol35–37. To test whether 
this could interfere with the cytotoxicity of pitavastatin, we prepared organic solvent extracts of different mouse 
chows and human foods and found that many, particularly sunflower oil, suppressed the activity of pitavastatin 
in cell growth assays as well as in caspase 3/7 assays in two separate cell lines (Fig. 4). Extracts from mouse chow 
also inhibited the activity of pitavastatin. To demonstrate the presence of geranylgeraniol in the extracts, the 
sunflower extracts were analysed by GC-MS. We confirmed the previously reported37 presence of geranylgeraniol 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 5410  | DOI:10.1038/s41598-017-05595-4
Figure 1. HMGCR is over-expressed in ovarian cancer cells and regulated by TP53. (a) The expression of 
HMGCR was measured by immunoblotting and quantified (b) in a panel of ovarian cancer cells and compared 
to non-cancerous cells including normal human ovarian epithelia (HOE), human foreskin fibroblasts (HFF) 
normal lung epithelia (NL20). (c) Wild (WT) and TP53 variants were over-expressed in SkOv-3 cells and 
p53 and HMGCR measured by immunoblotting. The numbers above the blots show the mean change in 
protein normalized to GAPDH (n = 3 lysates) and expressed as ratio of that measured in cells transfected 
with the vector. D. Ovcar-3 cells were transfected with non-targeting (NT) siRNA or 4 different p53 siRNA 
(#1, #2, #3, #4) and reduction in p53 and HMGCR protein confirmed by immunoblotting (n = 3 independent 
transfections). Expression was quantified and normalized to that in normal cells (mean ± S.D, n = 3, *paired t-
test, P < 0.05, compared to cells transfected with vector). HMGCR mRNA was measured by QPCR, normalized 
to GAPDH expression and expression was calculated as a fraction of that measured in cells transfected with NT 
siRNA (paired t-test, n = 3 independent transfections; *P < 0.05; **P < 0.005 compared to cells transfected with 
NT siRNA). Images presented in this panel were cropped to remove surrounding white space.
Figure 2. Pitavastatin inhibits the growth of cultures of ovarian cancer cells. The effect of pitavastatin was 
assessed in cell growth assays (mean IC50 ± S.D., n = 3–5 biological replicates) using monolayer (a) and spheroid 
cultures (b). (c) The growth inhibitory effects of pitavastatin (1 μM) on Ovcar-8 monolayer cultures were 
suppressed (*paired t-test, P < 0.01) by geranylgeraniol (G, 10 μM) but not farnesol (F, 10 μM).
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derivatives (Fig. S3). These data suggested that diet might have suppressed the activity of pitavastatin in our initial 
xenograft studies and may also have contributed to the lack of efficacy of statins in clinical trials.
We looked for an alternative food free of isoprenoids that could be used in these settings. Organic solvent 
extracts of the complete oral liquid food supplements Ensure Plus and Fresubin did not supress the activity of 
pitavastatin in cell growth or caspase assays (Fig. 4). In a xenograft study in which mice bearing Ovcar-4 tumours 
were fed Ensure Plus in place of regular chow, pitavastatin (59 mg/kg, b.i.d., p.o.) caused significant tumour regres-
sion (56 ± 12% of initial tumour volume, n = 7; P < 0.005; Fig. 5a) whereas tumours in mice which received the 
vehicle continued to grow (205 ± 71% of initial volume). Ki-67 staining was observed in 59 ± 12% of the tumour 
cells recovered from animals which received vehicle, but significantly fewer cells (34 ± 16%, P < 0.05) were Ki-67 
positive in the residual tumour tissue recovered from mice which received pitavastatin. To evaluate whether die-
tary geranylgeraniol could suppress the activity of pitavastatin, nude mice bearing Ovcar-4 tumours were main-
tained on Ensure Plus or Ensure Plus supplemented with 0.14 mg/mL geranylgeraniol. Both sets of mice where 
subsequently treated with pitavastatin. In the absence of dietary geranylgeraniol, pitavastatin caused tumour 
regression (61 ± 13% of initial volume, n = 4) whereas tumours in mice who received dietary geranylgeraniol and 
pitavastatin continued to grow and were significantly larger (182 ± 52% of initial volume, n = 4, P < 0.05; Fig. 5b) 
than the mice maintained on unsupplemented Ensure Plus. Tumours were collected 8 hours after the last drug 
administration to measure the trough pitavastatin concentration. The concentration of pitavastatin in tumours 
excised from animals receiving pitavastatin and geranylgeraniol was 3.1 μM, significantly lower than that meas-
ured in the Ovcar-3 tumours (Supplementary Figure 2). The drug was undetectable in the small residual Ovcar-4 
tumours that had regressed in the animals treated with pitavastatin alone.
Discussion
Our previously published study20 suggests that the physicochemical and pharmacological profile of pitavastatin 
makes it the statin most likely to be efficacious in oncology clinical trials. We have shown that pitavastatin induces 
apoptosis in ovarian cancer cells. Statins have demonstrated activity in several other cancer types13, suggesting 
Figure 3. Pitavastatin induces apoptosis. (a,b) Pitavastatin (1 μM (5 × IC50, chosen to ensure a synchronous 
response), for 48 h) increased caspase 8, 9 and 3/7 activities in Ovcar-8 cells (a) and Ovcar-3 cells (b) 
compared to cells treated with an equal concentration of DMSO solvent used to dissolve pitavastatin (paired 
t-test, *P < 0.05, n = 3 biological replicates; results expressed as a fraction of that measured after exposure to 
paclitaxel). (c) Pitavastatin (1 μM, 48 h, n = 3 biological replicates) caused PARP cleavage in Ovcar-8 cells and 
this was suppressed by geranylgeraniol (G, 10 µM) and mevalonate (M, 100 µM) but not farnesol (F, 10 µM). 
Images presented in this panel were cropped to remove surrounding white space. (d) Pitavastatin increased the 
release of ccCK18 into cell culture supernatant of both Ovcar-3 cells and Ovcar-8 cells compared to cells treated 
with solvent (paired t-test, **P < 0.005, n = 3 biological replicates, normalized to ccCK18 release caused by 
paclitaxel exposure).
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Figure 4. Ovcar-8 (a,c) or Ovcar-3 (b,d) cells were exposed to pitavastatin (1 μM) in the presence of solvent 
extracts (0.06% v/v) from the indicated human foodstuffs and mouse chow from different suppliers. (a,b) The 
number of cells remaining (mean ± S.D., expressed as a fraction of cells treated with solvent alone, n = 3–5 
biological replicates) after 72 h was determined by staining with SRB. The number of cells was significantly 
different to cells exposed to pitavastatin alone where indicated (paired t-test, *P < 0.05; **P < 0.005; 
***P < 1 × 10−4; ****P < 5 × 10−6). (c,d) Cells were exposed to pitavastatin and the solvent extracts as above 
and caspase 3/7 activity measured (mean ± S.D., n = 3 biological replicates, *significantly different from cells 
treated with pitavastatin alone, paired t-test, P < 0.05).
Figure 5. (a) Nude mice maintained on a diet of Ensure Plus and bearing subcutaneous Ovcar-4 tumours 
(mean volume 150 mm3, 6 animals per study arm) were treated twice daily with vehicle or pitavastatin-calcium 
(59 mg/kg, p.o.). After 28 days, tumour volume was significantly different in the mice receiving pitavastatin 
(*P < 0.005, t-test with Welch’s correction). Animal body weight increased throughout the course of the dosing 
period and no significant adverse events were observed. (b) Nude mice bearing subcutaneous Ovcar-4 tumours 
(mean volume 220 mm3, 4 animals per study arm) were treated twice daily with pitavastatin-calcium (59 mg/
kg, p.o.) for days 1–14 while being provided a diet of either Ensure Plus or Ensure Plus supplemented with 
0.14 mg/mL geranylgeraniol. Animal body weight increased throughout the course of the dosing period and no 
significant adverse events were observed. Mice were returned to regular chow on day 16. After 28 days, tumour 
volume was significantly larger in the animals receiving dietary geranylgeraniol (#P < 0.05, t-test with Welch’s 
correction).
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that pitavastatin may useful to treat a range of cancers. Indeed pitavastatin has been shown to inhibit the growth 
of glioblastoma cells in xenograft studies in mice38. However, we report for the first time that restriction of diet to 
eliminate geranylgeraniol allows statins to induce tumour regression.
Pitavastatin was effective in all of the cell lines tested, with potencies differing by approximately 10-fold 
between different cell lines. This may reflect a fundamental role of the mevalonate pathway in ovarian cancer cell 
biology. In support of this, we observed that increased expression of both wild-type and gain-of-function variants 
of TP53 led to increased HMGCR expression. Together with the wide spread dysregulation of TP53 in ovarian 
cancer7, and the detection of HMGCR in a large proportion of ovarian cancer tumours8, this suggests that a sig-
nificant proportion of ovarian cancer patients may be candidates for treatment with pitavastatin. The selection of 
patients for statin therapy may be further guided by gene expression profiles which predict statin sensitivity39. Of 
particular interest, we found that pitavastatin retained its activity in matched cells derived from patients before 
and after the onset of clinical drug resistance. This raises the possibility that statins may be useful to treat patients 
with chemotherapy-resistant disease, a patient population currently lacking adequate therapy.
We found that supplementing the diet of animals with geranylgeraniol prevented the tumour regression 
caused by pitavastatin. Geranylgeraniol is likely to be converted into its pyrophosphate inside cells because this 
is the substrate for geranylgeranyl transferases. We administered the geranylgeraniol rather than its pyrophos-
phate form because we anticipated that it is unlikely that the pyrophosphate would be orally bioavailable, due to 
reduced membrane permeability compared to the free alcohol and hydrolysis of the phosphoester in the acidic 
environment of the stomach. Although methods to measure geranylgeranyl pyrophosphate have been developed40 
additional methods to evaluate the bioavailability of different geranylgeraniol derivatives are needed.
Although we have used pitavastatin at a relatively high dose/concentration, there is good reason to believe its 
activity is mediated by inhibition of the mevalonate pathway. Firstly, products of the mevalonate pathway, ger-
anylgeraniol and mevalonate, but not farnesol, reverse the activity of pitavastatin and other statins20 in vitro; we 
further show here that geranylgeraniol inhibits the activity of pitavastatin in animal studies. Farnesol presumably 
fails to do the same because it requires the production of 5 carbon isoprenoids for it to be converted into gera-
nylgeraniol, and this is blocked by pitavastatin. Secondly, several studies, including our own unpublished observa-
tions, show that statins (lovastatin, simvastatin, fluvastatin, pitavastatin) interact synergistically with inhibitors of 
geranylgeranyl diphosphate synthase41 or farnesyldiphosphate synthase42–45. For two drugs to act synergistically 
their molecular targets must lie on interacting pathways, so synergy between statins and other inhibitors of the 
mevalonate pathway is consistent with pitavastatin acting through inhibition of the mevalonate pathway. Thus, 
the activities of statins are enhanced by drugs which inhibit the mevalonate pathway and suppressed by addition 
of metabolites produced by the mevalonate pathway, strongly supporting the contention that pitavastatin causes 
cell death through inhibition of the mevalonate pathway.
The effect of diet on the activity of pitavastatin which we have observed may explain the discrepancies between 
positive preclinical studies of statins in cancer, retrospective clinical studies in which statins have been associated 
with modest improvements in cancer outcome, and prospective clinical trials which have not yet demonstrated 
widespread efficacy. In retrospective studies of patients receiving statins for hypercholesterolaemia, patients may 
have received dietary advice to reduce fat intake but it is unlikely that all sources of dietary geranylgeraniol were 
eliminated. Analysis is also complicated because patients in these studies received different statins at different 
doses. The relatively large cohorts of patients in these retrospective trials, together with reduced dietary isopre-
noids may have allowed modest survival benefits to be detected. We have shown continual inhibition of HMGCR 
is necessary to cause cancer cell death20. The failure to ensure continual inhibition of HMGCR, particularly a 
problem with a low dose of a statin with a short half-life and which is administered once daily, may have also 
prevented more significant clinical results from being obtained. We consider that successful prospective clinical 
trials of statins in cancer can best be designed by evaluating relatively high doses of a potent lipophilic statin 
with an adequate half-life, which is administered at a suitable dosing frequency to ensure continual inhibition of 
HMGCR, and dietary sources of geranylgeraniol or other mevalonate pathway metabolites should be controlled. 
No trials published to date have addressed all three factors, potentially explaining the lack of notable clinical 
success with statins in oncology to date. We have identified one potential diet that could be used in clinical trials 
for the duration of statin treatment – in our studies we saw tumour regression within 2 weeks. It is feasible that 
patients could be restricted to a diet of Ensure Plus for such a period, although it is clearly desirable to identify 
additional foods that do not interfere with the activity of statins. We consider that pitavastatin, which has gained 
regulatory approval in both the US and the European Union for the treatment of hypercholesterolaemia, is the 
most appropriate statin for clinical oncology studies because of its lipophilicity, relatively long half-life and oral 
bioavailability29. Statins have shown efficacy in vitro in a broad range of cancer types13, suggesting that pitavas-
tatin warrants preclinical and clinical studies in these cancers but taking into account the factors which we have 
identified. This may lead to the use of statins in a range of cancer types.
We administered pitavastatin at a relatively high dose (½ MTD). This is significantly higher than the dose 
of pitavastatin (up to 4 mg) currently used to treat hypercholesterolaemia but this dose allowed us to achieve 
microMolar concentrations of drug in the tumours. An issue that may limit the use of statins, particularly at high 
doses, is that statins have been associated with myopathy29 and in some cases this can result in rhabodomyolysis. 
It will be important to evaluate in clinical trials whether a suitable dose can be found which is efficacious without 
unacceptable toxicity. However, clinical trials of high dose statins have not recorded myopathy within 1–2 weeks 
of commencing therapy, although only small numbers of patients have been assessed. Cycles of brief (1–2 weeks) 
high-dose pitavastatin therapy may minimize the incidence if myopathy. Clinical studies, designed to the criteria 
which we have identified, are needed to evaluate escalating doses of pitavastatin to define the therapeutic window 
for pitavastatin in an oncology setting.
Lastly, although the goal of these studies was to explore the potential for pitavastatin to be used to treat cancer, 
our observations have broader implications. There is currently particular interest in targeting several metabolic 
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pathways to treat cancer and clinical trials of such drugs are underway46. We suggest that clinical trials of drugs 
targeting metabolic pathways should be designed to take into account the potential for patients to ingest metab-
olites on the pathway which is being targeted and which could potentially impair drug efficacy. It seems prudent 
to assess this in preclinical studies, similar to those we report here, evaluating different dietary sources of these 
metabolites prior to conducting clinical trials.
Materials and Methods
Cell Culture. Cell lines were obtained from either ATCC, ECACC, NIH or JCRB. Human ovarian cancer 
cell lines (A2780, cisA2780, Igrov-1, Skov-3, Ovcar-3, Ovcar-4, Ovcar-5,Ovcar-8, COV-318, COV-326 Ovsaho, 
PEA1, PEA2, PEO1, PEO4), human ovarian epithelial (HOE) cells and primary human foreskin fibroblasts (HFF) 
were grown in RPMI supplemented with 10% FCS, 50 U/mL Penicillin/Streptomycin and 2 mM Glutamine. The 
NL20 cell line was grown in Ham’s F12 medium supplemented with 4% FCS, 1.5 g/L sodium bicarbonate, 2.7 g/L 
glucose, 2 mM glutamine, 0.1 mM non-essential amino acids, 0.005 mg/mL insulin, 10 ng/mL epidermal growth 
factor, 0.001 mg/mL transferrin and 500 ng/mL hydrocortisone. Cells were incubated at 37 °C and 5% CO2 and 
tested for mycoplasma.
Cell Growth Assays. Cell growth assays were performed as previously described47. Cells (5000 cells/well 
except for A2780, cisA2780 and Ovcar-8, where 2000 cells/well were used) were seeded in 96-well plates in 80 μL 
of growth medium. After 24 h, 20 μL of 18 different concentrations of drug or food extract at 5 times the required 
concentration or a drug solvent control was added to the cells. After incubation for a further 72 h, the growth 
medium was removed and the cells in each well were fixed in 100 μL 10% trichloroacetic acid (TCA) on ice for 
30 min. The plates were washed three times in water, dried and stained in 0.4% sulforhodamine B (SRB) in 1% ace-
tic acid for 30 minutes. After washing three times in 1% acetic acid and drying, the dye was solubilised in 100 μL 
10 mM Tris (pH 10) and the absorbance at 570 nm (A570) was determined using a BioTek Synergy 2 multi-mode 
microplate reader. For experiments evaluating the ability of isoprenoids to reverse the effect of pitavastatin, cells 
were simultaneously exposed to either 100 μM mevalonate, 10 μM farnesol, 10 μM geranylgeraniol or DMSO.
Three-Dimensional Spheroid Culture and ATP Assays. Ovcar-3 (5 × 105 cells/mL), Ovcar-5 (1 × 106 
cells/mL), Ovcar-8 (1.25 × 105 cells/mL) and Igrov-1 (2 × 106 cells/mL) cells were prepared as cell suspensions 
in growth medium. One 20 μL drop of cell suspension was added to each inner ring of the lids of 48-well plates. 
Outer rings contained a 20 μL drop of growth medium and 300 μL of sterile water was added to each well beneath 
the rings to maintain a humid atmosphere and minimise evaporation. The lids were inverted over the plates and 
incubated for 7 days. After 1 week, the spheroids were exposed to 5 μL growth medium containing pitavastatin 
or solvent and incubated for a further 72 h. The spheroids were then collected using a wide bore pipette into 
opaque-walled multiwell plates containing 20 μL of PBS and an equal volume of CellTiter-Glo reagent was added 
in order to measure ATP. Spheroid lysis was confirmed by microscopy to ensure penetration of the reagent into 
the spheroid. Luminescence was measured using a BioTek Synergy 2 multi-mode microplate reader.
ImmunoBlotting. For western blotting, 5 × 105 cells were exposed to pitavastatin in the presence or absence 
of 100 μM mevalonate, 10 μM farnesol, 10 μM geranylgeraniol or DMSO (these concentrations were found in 
preliminary experiments to be both soluble in aqueous media and not cytotoxic). After 48 h, the cells were col-
lected, washed in PBS and lysed in a modified RIPA containing protease inhibitors48. Protein concentration was 
determined using a BCA assay and samples normalized to load equal mass of protein in each lane (10–20 μg). 
After electrophoresis and transfer to PVDF, membranes were incubated with anti-PARP antibody (1/1000, #9542, 
Cell Signaling), anti-HMGCR [EPR1685(N)] antibody (1/1000, AB174830, Abcam), p53 (1/5000, Ab179477, 
Abcam) or anti-GAPDH antibody (1/5000, MAB374, Millipore) as a loading control. Bands were quantified using 
AlphaView SA (ProteinSimple) and normalized to GAPDH.
Caspase 3/7, 8 and 9 Assays. Ovcar-8 (2000 cells/well) and Ovcar-3 (5000 cells/well) cells were incubated 
in 80 μL growth medium in a 96-well plate for 24 h. Cells were then supplemented with 20 μL growth medium 
containing pitavastatin, paclitaxel or solvent. In other experiments, Ovcar-8 and Ovcar-3 cells were exposed to 
pitavastatin for 48 h, then 25 μL of Caspase-Glo 3/7, 8 or 9 reagent (Promega) was added and cells were incubated 
for 30 minutes at room temperature in the dark. A BioTek Synergy 2 multi-mode microplate reader was used to 
measure luminescence.
M30 CytoDeath ELISA. Ovcar-8 (2000 cells/well) or Ovcar-3, (5000 cells/well) were incubated in 100 μL 
growth medium in a 96-well plate for 24 h and then exposed to pitavastatin at five times the IC50 measured in cell 
growth assays, paclitaxel (50 nM) or solvent. After 72 h, the supernatant was collected and centrifuged at 10,000 g 
for 10 min at 4 °C. The M30 CytoDeath ELISA (Peviva) was completed following the manufacturer’s instructions. 
A450 was measured using a BioTek Synergy 2 multi-mode microplate reader.
siRNA Studies. Si-genome p53 siRNA (p53#1, GAAAUUUGCGUGUGGAGUA; p53#2, GUGCAGCUGUG 
GGUUGAUU; p53#3, GCAGUCAGAUCCUAGCGUC; p53#4, GGAGAAUAUUUCACCCUUC), a 
non-targeting siRNA NT-1 or SMARTpool (Dharmacon) comprising the same oligos were used to inhibit the 
expression of TP53. Ovcar-3 cells ((5000 cells/well) were plated in a 96 well plate in 80 µl of antibiotic-free growth 
medium per well). The following day the cells were transfected with 0.1% Dharmafect-1 and 100 nM siRNA as 
previously described49. The next day, the media were replaced with 100 µL of fresh antibiotic-free growth media. 
Knockdown of TP53 expression was assessed by immunoblotting and QPCR.
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Transient expression of p53. Expression studies were approved by the Keele genetic modifications of 
microorganisms committee. SkOv-3 cells (32,000 cells per well of a 24 well plate) were transfected with 0.1 μg 
CMV-Neo-Bam (vector), pCMV-Neo-Bam p53 wt, pCMV-Neo-Bam p53 R175H, pCMV-Neo-Bam p53 R273H, 
pCMV-Neo-Bam p53 R248W (Addgene) and 0.2 μL of Lipofectamine 2000 as previously described47. Protein 
expression was measured by immunoblotting.
Xenograft studies. Ovcar-3 xenograft studies were completed by Charles River Discovery Research Services 
in Morrisville, North Carolina. Animal studies at Charles River were approved by Charles River Institutional 
Animal Care and Use Committee and the studies complied with all relevant guidelines and regulations. Female 
CB17 severe combined immunodeficiency (SCID) mice at an age of 8–12 weeks were subcutaneously injected in 
the flank with 1 mm3 Ovcar-3 tumour fragments. When tumours reached an average of 100 mm3, animals were 
assigned randomly either to the drug or vehicle arm of the trial. A separate cohort received paclitaxel as a positive 
control. Mice received either 79 mg/kg (representing ½ maximum tolerated dose) pitavastatin calcium suspension 
p.o. prepared in 0.5% carboxymethyl cellulose in sterile water or vehicle every 12 h for 33 days (10 mice per group).
A subsequent study with Ovcar-4 was approved by Keele Animal Welfare and Ethical Review Body and con-
ducted under a license granted under the Animal (Scientific Procedures) Act 1986 following institutional guide-
lines. For Ovcar-4 xenograft studies, 4 week old female NCR Nu/Nu female mice (Envigo) were injected s.c. 
with 3 million Ovcar-4 cells suspended in 50% cultrex in RPMI. When the tumours were established, animals 
were adapted for one week to a diet of Ensure Plus ad libitum and regular chow was withdrawn. Pairs of animals 
with comparable size tumours were assigned randomly to either arm of the study and received either 59 mg/
kg (representing ½ maxium tolerated dose) p.o. pitavastatin calcium suspension (8 mg/mL) twice daily in 0.5% 
carboxymethyl cellulose in sterile water or the drug vehicle. Each arm of the study comprised 6 animals. Tumour 
volume and animal weight was monitored twice weekly. The investigators were not blinded to the drug treatment.
In experiments to measure the effect of geranylgeraniol, animals with established tumours were again adapted 
to a diet of Ensure Plus one week before the start of the experiment. The animals were randomized to either arm 
of the study as described above (4 animals per arm). All animals received pitavastatin as described above from 
days 1–14. The animals received either Ensure Plus or Ensure Plus freshly supplemented daily with 0.14 mg/
mL geranylgeraniol (Santa Cruz) from day 1-day 16. This concentration of geranylgeraniol was estimated to be 
equivalent (per kg bodyweight) to that which has previously been delivered to rats50. On day 17, all animals were 
switched back to regular mouse chow.
Extraction and Detection of Pitavastatin in Ovcar-3 Tumours. 50–200 mg of each tumour sample was 
homogenised in 200 μL PBS using a Dounce homogeniser. The resulting suspension was centrifuged at 10,000 g 
for 10 min at 4 °C and the supernatant was collected. Supelclean LC-18 solid phase extraction (SPE) columns 
(SupelCo) were conditioned with 3 mL 99% methanol, followed by 3 mL deionised water, and then 3 mL 0.5 M 
monobasic potassium phosphate. The sample was then applied and the column washed with 3 mL 0.5 M monobasic 
potassium phosphate and 3 mL deionised water. Pitavastatin was eluted with 3 mL methanol and the eluate dried. 
The residue was re-suspended in 100 μL 99% methanol for HPLC analysis or growth medium for cell growth assays.
For HPLC analysis, samples were diluted in acetonitrile and a 20 μL sample analysed on a reverse-phase C18 
column (Metlab Supplies) with a mobile phase of acetonitrile:water with 0.1% formic acid (65:35) and 1 mL/min 
flow rate. Pitavastatin was detected with an excitation of 245 nm and an emission of 420 nm and quantified using 
standards treated in the same way.
Alternatively, a bioassay was performed in which a range of concentrations of the extracts were added to 
Ovcar-8 cells and the effect of the extract in cell growth assays, performed as described above, was assessed, In 
parallel, the effect of known concentrations of pitavastatin was measured and used to estimate the concentration 
of pitavastatin in the extracts.
Extraction and Detection of Pitavastatin in Ovcar-4 Tumours. Tissue from tumour drug accumu-
lation studies were prepared for analysis by homogenisation in a Dounce homogenizer (4 μL per mg of tissue) 
in deionized water. Three parts isopropanol containing 1 µg/mL internal standard simvastatin was added to one 
part sample homogenate and vials were vortexed for 30 seconds and placed on ice. Samples were centrifuged 
(8000 g, 20 minutes, 4 °C) and supernatant collected. The extraction efficiency of pitavastatin and internal stand-
ard simvastatin was 72% and 97% respectively. The HPLC-MS/MS system used for sample analysis consisted of an 
autosampler model Dionex Ultimate 3000, and an Applied Biosystems 3200 QTrap mass spectrometer (Thermo, 
UK) utilising a Turbo Ionspray source. The precursor mass-to-charge ratio, collision-induced mass shift and 
optimal detection settings for pitavastatin and internal standard simvastatin were obtained from previous pub-
lications51, 52. Chromatographic separation was performed at 25 °C on a Hypersil Gold reverse-phase C-18 3 µM 
column (50 × 2.1 mm i.d., ThermoFisher, UK). An isocratic mobile phase was utilised during each 10 minute run 
at a flow rate of 0.3 mL/minute and consisted of 70% methanol, 30% MS grade water and 0.05% formic acid. The 
retention time of pitavastatin and internal standard simvastatin was 3.31 minutes and 4.92 minutes, respectively, 
and the lowest limit of pitavastatin quantification was 30.6 ng/mL. The high concentration quality controls (HQC, 
1900 ng/mL, n = 3) had a mean intra-day accuracy and precision of 97.5% and 95.5%, respectively. The medium 
concentration quality controls (MQC, 600 ng/mL, n = 3) had a mean intra-day accuracy and precision of 94.7% 
and 97.4%, respectively. The low concentration quality controls (LQC, 60 ng/mL, n = 3) had a mean intra-day 
accuracy and precision of 88.3% and 95.0%, respectively. All QCs tested gave higher than 85% accuracy and pre-
cision and the linear range for pitavastatin quantification was 30.6–2000 ng/mL.
Preparation of food extracts and analysis by GCMS. Kinuhikari rice36 was obtained from the cultivator 
and oils were purchased from food stores in the UK. Ensure Plus Raspberry Flavour Drink and Fresubin 2 kcal Vanilla 
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Flavour Drink were donated by a local pharmacy. Mouse chows included Lab Diet NIH 31 0045117 from Charles 
River in North Carolina, Special Diets Services 801960 BK001(E) from Keele University in the UK and Open Source 
Diets D11112201 from University of British Columbia in Canada. Solid foods (50 g) were homogenized in a food pro-
cessor in 30 mL methanol and extracted by further additions of 30 mL chloroform and 30 mL methanol. The extracts 
were filtered and evaporated to dryness. Alternatively, liquid foodstuffs were transferred to a separating funnel and 
extracted with 60 mL methanol and 30 mL chloroform. The lower lipid phase was evaporated to dryness. The residues 
were dissolved in 25 mL ethanol and hydrolysed with 25 mL 5 M potassium hydroxide at 56 °C for 1 h. After cooling, 
and neutralization with 25 mL 5 M hydrochloric acid the solution was partitioned with 120 mL n-hexane, 30 mL water 
and 30 mL ethanol. The upper organic phase was evaporated to dryness and dissolved in DMSO for analysis.
Chemical Analysis: Gas Chromatography – Mass Spectrometry. Dried sunflower oil extract were 
re-dissolved in hexane before analysis. Chemical analysis of these sunflower extracts (2 μL) was carried out on 
an Agilent Technologies 7890 N Network GC with a split/splitless injector at 250 °C in split mode (ratio 100:1), 
a Agilent VF-5HT capillary column (30 m × 0.25 mm ID, 0.1 μm film thickness) and coupled to an Agilent 
5975 Network Mass Selective Detector. The GC was coupled to a computer and data processed with Agilent 
Chemstation software. Elution was carried out with helium at 1 mL/min. The oven temperature was programmed 
to be held at 35 °C for 2 minutes then ramped to 300 °C at 5 °C/min and then from 300 °C to 350 °C at 10 °C/min. 
The mass spectrometer was operated in Electron Ionisation mode at 70 eV, scanning from 40–800 amu at 1.5 scans 
s−1. Compounds were identified using a library search (NIST08) and the diagnostic fragmented ions.
Statistical Methods. To analyse cell growth assays, Graphpad Prism was used to fit a 4 parameter Hill 
equation to the data. The statistical methods used for each experiment are presented in the relevant figure legends.
Data availability. The datasets generated during and/or analysed during the current study are either 
included in the published article or are available from the corresponding author on reasonable request.
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